导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.93% | 1221/4773 |
| 近一周 | -3.34% | 3945/5458 |
| 近一月 | -1.45% | 1185/5421 |
| 近一季 | 1.15% | 708/5205 |
| 近半年 | -4.34% | 2647/4920 |
| 近一年 | 12.42% | 849/4361 |
| 近两年 | 89.99% | 696/2954 |
| 近三年 | 65.26% | 379/2253 |
| 成立以来 | 136.19% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.14% 1042/4961 |
11.06% 2373/5312 |
- - |
- - |
| 2025 | 43.52% 665/4813 |
5.12% 824/3635 |
7.63% 371/4076 |
21.12% 1848/4524 |
4.73% 496/4813 |
| 2024 | 9.64% 1454/3463 |
-5.43% 1896/2808 |
-1.38% 1054/3014 |
14.44% 1972/3129 |
2.72% 903/3463 |
| 2023 | -5.31% 728/2656 |
1.59% 1539/2280 |
-1.31% 471/2385 |
-5.21% 1292/2515 |
-0.37% 207/2655 |
| 2022 | -32.88% 1689/2207 |
-16.17% 1111/1919 |
3.48% 1146/2016 |
-20.77% 1876/2113 |
-2.34% 1797/2208 |
| 2021 | 9.65% 453/1822 |
-5.74% 952/1255 |
15.77% 222/1330 |
-4.90% 748/1466 |
5.65% 276/1822 |
| 2020 | 32.70% 478/1250 |
-1.12% 204/1028 |
24.32% 174/1067 |
0.99% 1034/1164 |
6.90% 737/1184 |
| 2019 | 61.00% 50/1092 |
34.12% 122/754 |
-4.88% 445/804 |
15.17% 16/850 |
9.57% 219/918 |
| 2018 | -26.21% 375/834 |
- - |
- - |
- - |
-13.81% 557/691 |
| 2017 | 4.74% 382/714 |
- - |
- - |
- - |
- - |
| 2016 | -19.57% 434/605 |
- - |
- - |
- - |
- - |
| 2015 | 26.05% 88/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 广发百发100指数E VS. 长安沪深300非周期A(740101) |